---
DrugClass: "[[Menopause and Andropause Drugs]]"
SubClass: Hormonal Therapy for Breast, Endometrial, and Prostate Cancer
DrugClassAdverse: 
DrugClassContra: 
BrandName: Nilandron
SecondaryDrugClass: 
SecondarySubClass: 
SecondaryAdverse: 
SecondaryContra: 
ThirdDrugClass: 
ThirdSubClass: 
ThirdAdverse: 
ThirdContra: 
FourthDrugClass: 
FourthSubClass: 
FourthAdverse: 
FourthContra: 
Chapter: "45"
KindleLinkChap: "[Chapter 45](kindle://book?action=open&asin=B09FRF11YJ&location=26138)"
KindleLink: 
tags:
  - Drug
  - Pharmacology
Course: Pharmacology
ChemLink: https://pubchem.ncbi.nlm.nih.gov/#query=
aliases: 
SubCat: Antiandrogens
---
```smiles
CC1(C(=O)N(C(=O)N1)C2=CC(=C(C=C2)[N+](=O)[O-])C(F)(F)F)C
```

### Brand name
`=this.BrandName`

### Generic name
`= this.file.name`

### Drug class 
`= this.DrugClass`
	`= this.DrugClass.KindleLinkChap`

### Dosage & Usage
Prostate cancer 
300 mg/day for 1 month, then 150 mg/day orally 

### Contraindications
See `= this.DrugClassContra`

### Mechanisms of Action


### Side/Adverse Effects
See `= this.DrugClassAdverse`
Pain, headache, [[asthenia]], flu-like symptoms, insomnia, nausea, constipation, testicular atrophy, dyspnea 

### Interactions

`= this.ChemLink+this.file.name`

